↓ Skip to main content

European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency

Overview of attention for article published in European Respiratory Journal, November 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
33 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
125 Dimensions

Readers on

mendeley
129 Mendeley
Title
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency
Published in
European Respiratory Journal, November 2017
DOI 10.1183/13993003.00610-2017
Pubmed ID
Authors

Marc Miravitlles, Asger Dirksen, Ilaria Ferrarotti, Vladimir Koblizek, Peter Lange, Ravi Mahadeva, Noel G. McElvaney, David Parr, Eeva Piitulainen, Nicolas Roche, Jan Stolk, Gabriel Thabut, Alice Turner, Claus Vogelmeier, Robert A. Stockley

Abstract

α1-antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease. The pulmonary emphysema in AATD is strongly linked to smoking, but even a proportion of never-smokers develop progressive lung disease. A large proportion of individuals affected remain undiagnosed and therefore without access to appropriate care and treatment.The most recent international statement on AATD was published by the American Thoracic Society and the European Respiratory Society in 2003. Since then there has been a continuous development of novel, more accurate and less expensive genetic diagnostic methods. Furthermore, new outcome parameters have been developed and validated for use in clinical trials and a new series of observational and randomised clinical trials have provided more evidence concerning the efficacy and safety of augmentation therapy, the only specific treatment available for the pulmonary disease associated with AATD.As AATD is a rare disease, it is crucial to organise national and international registries and collect information prospectively about the natural history of the disease. Management of AATD patients must be supervised by national or regional expert centres and inequalities in access to therapies across Europe should be addressed.

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 129 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 18%
Student > Master 14 11%
Other 13 10%
Student > Bachelor 12 9%
Student > Ph. D. Student 9 7%
Other 25 19%
Unknown 33 26%
Readers by discipline Count As %
Medicine and Dentistry 59 46%
Biochemistry, Genetics and Molecular Biology 9 7%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Agricultural and Biological Sciences 3 2%
Engineering 2 2%
Other 9 7%
Unknown 41 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2021.
All research outputs
#1,161,270
of 17,342,898 outputs
Outputs from European Respiratory Journal
#799
of 7,517 outputs
Outputs of similar age
#40,154
of 418,456 outputs
Outputs of similar age from European Respiratory Journal
#34
of 148 outputs
Altmetric has tracked 17,342,898 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,517 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 418,456 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 148 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.